ESI gets rights to diabetes technology
Thursday, 19 December, 2002
Singapore-based stem cell company ES Cell International (ESI) has acquired patent rights to technology relating to the transformation of stem cells into insulin-producing cells from US company Curis.
Under the terms of the agreement, ESI will be responsible for continuing the development and testing of Curis' diabetes stem cell technologies.
According to Robert Klupacs, CEO of ESI, the acquisition will enhance ESI's diabetes cell therapy program and complements other technology the company has licensed in for the program.
"Accessing both Curis' world-class technologies and research capabilities will significantly accelerate our ability to bring cell-based therapies for diabetes to the clinic," Klupacs said in a statement.
ESI is developing therapeutic technologies for the treatment of diabetes and Parkinson's disease using embryonic and adult stem cells.
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
Plug-and-play test evaluates T cell immunotherapy effectiveness
The plug-and-play test enables real-time monitoring of T cells that have been engineered to fight...
Common heart medicine may be causing depression
Beta blockers are unlikely to be needed for heart attack patients who have a normal pumping...
